A study using MagnetisMM-3 trial data reports that fixed-dose elranatamab maintains consistent pharmacokinetics, safety, and response rates across patient body-weight quartiles in multiple myeloma. The findings address a practical question in bispecific dosing—whether fixed dosing compromises exposure or outcomes in heavier or lighter patients. By evaluating multiple weight bands within the trial framework, the work supports a simplification strategy for real-world administration and may reduce complexity in dosing decisions. In an era where manufacturing and administration efficiency increasingly matter, the dataset offers evidence that fixed-dose regimens can be deployed without obvious compromises across body size subgroups.